The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes
Open accessAbstract
The objective of this study was to determine the prevalence, mutual associations, clinical manifestations, and diagnoses associated with serum autoantibodies, as detected using recently available immunoassays, in patients with autoimmune myositis (AIM). Sera and clinical data were collected from 100 patients with AIM followed longitudinally. Sera were screened cross-sectionally for 21 autoantibodies by multiplex addressable laser bead immunoassay, line blot immunoassay, immunoprecipitation of in vitro translated recombinant protein, protein A assisted immunoprecipitation, and enzyme-linked immunosorbent assay. Diagnoses were determined using the Bohan and Peter classification as well as recently proposed classifications. Relationships between autoantibodies and clinical manifestations were analyzed by multiple logistic regression. One or more autoantibodies encompassing 19 specificities were present in 80% of the patients. The most common autoantibodies were anti-Ro52 (30% of patients), anti-Ku (23%), anti-synthetases (22%), anti-U1RNP (15%), and anti-fibrillarin (14%). In the presence of autoantibodies to Ku, synthetases, U1RNP, fibrillarin, PM-Scl, or scleroderma autoantigens, at least one more autoantibody was detected in the majority of sera and at least two more autoantibodies in over one-third of sera. The largest number of concurrent autoantibodies was six autoantibodies. Overall, 44 distinct combinations of autoantibodies were counted. Most autoantibodies were unrestricted to any AIM diagnostic category. Distinct clinical syndromes and therapeutic responses were associated with anti-Jo-1, anti-fibrillarin, anti-U1RNP, anti-Ro, anti-Ro52, and autoantibodies to scleroderma autoantigens. We conclude that a significant proportion of AIM patients are characterized by complex associations of autoantibodies. Certain myositis autoantibodies are markers for distinct overlap syndromes and predict therapeutic outcomes. The ultimate clinical features, disease course, and response to therapy in a given AIM patient may be linked to the particular set of associated autoantibodies. These results provide a rationale for patient profiling and its application to therapeutics, because it cannot be assumed that the B-cell response is the same even in the majority of patients in a given diagnostic category.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances and applications of multiplexed diagnostic technologies in autoimmune diseases
Fritzler, M. (2006) · Lupus · doi:10.1191/0961203306lu2327oa · Cited by 78
Self-citation
Cited by
Koenig, M., Joyal, F., Fritzler, M. J., Roussin, A., Abrahamowicz, M., Boire, G., Goulet, J., Rich, É., Grodzicky, T., Raymond, Y., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24038 · Cited by 615
Self-citationAutoantibodies in Polymyositis and Dermatomyositis
Ghirardello, A., Bassi, N., Palma, L., Borella, E., Domeneghetti, M., Punzi, L., & Doria, A. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0335-1 · Cited by 461
Lega, J.-C., Fabien, N., Reynaud, Q., Durieu, I., Durupt, S., Dutertre, M., Cordier, J.-F., & Cottin, V. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.03.004 · Cited by 286
Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis
Hoshino, K., Muro, Y., Sugiura, K., Tomita, Y., Nakashima, R., & Mimori, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq153 · Cited by 260
Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen
Mahler, M., Fritzler, M. J., & Satoh, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.11.007 · Cited by 40
Self-citation
Metadata
- Authors
- Koenig, M., Fritzler, M. J., Targoff, I. N., Troyanov, Y., & Senécal, J.-L.
- Venue
- Arthritis Research & Therapy
- Published
- 2007-08-09
- Volume
- 9
- Issue
- 4
- Pages
- R78-R78
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1964495124
- Cited by
- 199
- References
- 1
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.